{"id":"W4389220971","doi":"10.1182/blood-2023-174209","title":"Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Cytokine release syndrome; Regimen; Lymphoma; Interim analysis; Clinical endpoint; Refractory (planetary science); Gastroenterology; Diffuse large B-cell lymphoma; Oncology; Clinical trial; Cancer; Immunotherapy; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007008878,0.0004548303,0.0008839504,0.0002473439,0.0001971858,0.0006694723,0.0003153166,0.0003111259,0.001558571],"category_scores_gemma":[0.0004248362,0.0002339834,0.0004855389,0.0002481596,0.000299463,0.0004061996,0.0001707744,0.001056536,0.0004236902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006552853,"about_ca_system_score_gemma":0.0005172978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004544169,"about_ca_topic_score_gemma":0.001965714,"domain_scores_codex":[0.999796,0.00007614762,0.00001723581,0.00004037614,0.00003077593,0.0000394546],"domain_scores_gemma":[0.9997632,0.00003698697,0.00005373946,0.0000227766,0.00001493707,0.0001084597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3661629,0.03274744,0.04478473,0.0009401898,0.001896565,0.0006181373,0.0004594809,0.003673364,0.1842304,0.0002729393,0.004383821,0.3598302],"study_design_scores_gemma":[0.1938279,0.6245148,0.1331048,0.0001002441,0.001641358,0.002227075,0.0001904652,0.004223831,0.02794272,0.0002810815,0.0118908,0.00005483416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967764,0.001201838,0.0002923397,0.00009761869,0.00001691017,0.0003210938,0.0002996282,0.00004425944,0.0009498519],"genre_scores_gemma":[0.997838,0.0004815588,0.0004299084,0.0001214508,0.00002472638,0.0001383858,0.0004445105,0.000007605667,0.0005138256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001558571,"threshold_uncertainty_score":0.005213916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01539641242473751,"score_gpt":0.2883512494041665,"score_spread":0.272954836979429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}